Abstract
The goal of maximizing efficacy and minimizing antimicrobial resistance can be termed optimizing therapy. To achieve optimal therapy, a number of outcomes must be met (Table 1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Paladino JA. Streamlining antibiotic therapy: clinical application of pharmacokinetic and pharmacodynamic principles. J Osteopath Med 1991; 5:16–25.
Liss RH, Batchelor FR. Economic evaluations of antibiotic use and resistance - a perspective: report of task force 6. Rev Infect Dis 1987; 9 (suppl 3): S297–312.
Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9:1065–78.
Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32(Suppl l):Sl-8.
Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance: report of the NNRSG. Diagn Microbiol Infect Dis. 1992; 15(suppl):37S-42S.
Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23:118–24.
Hyatt JM, Nix DE, Stratton CW, Schentag JJ. Relative potential for five classes of antimicrobial agents, alone and in combination, to select/induce oxacillin resistance in susceptible Staphylococcus aureus. 35th ICAAC meeting, Abstract C129, San Francisco, CA September 20, 1995.
Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, Cumbo TJ. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRS A infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998; 26:1204–14.
Fridkin SF, Edwards JR, Tenover FC, Gaynes RP, McGowan JE Jr. Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. Clin Infect Dis 2001; 33:324–30.
Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones using pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000; 20:417–28.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1–12.
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28:143–60.
Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics, 3 Edition. Vancouver, WA: Applied Therapeutics, Inc., 1992; Chapter 2; 1–43.
Peck CC, D’Argenio DZ, Rodman JH. Analysis of pharmackinetic data for individualizing drug dosage regimens. In Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. 3 Edition, Vancouver, WA.; Applied Therapeutics, Inc.; 1992; Chapter 3; 1–31.
Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Disl991; 74(suppl.):63–70.
Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornself B, Reichl V, Natarajan J, Corrado M. Pharmacodynamics of levofloxacin. JAMA 1998; 279:125–9.
Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108:835–40.
Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP, Ann Pharmacotherapy 1991; 25:1050–7.
Schentag JJ, Ballow CM, Paladino JA, Nix DE. Dual individualization of antibiotics. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Vancouver WA. Applied Therapeutics, Inc. 3 Edition; 1992; 17:1–20.
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073–81.
Nix DE, Sands MF, Peloquin CA, Vari AJ, Cumbo TJ, Vance JW, Fracasso JE, Schentag JJ. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Am J Med 1987; 82 (suppl 4A):352–6.
Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW. Role for dual individualization with cefmenoxime. Am J Med 1984; 77(suppl 6A):43–50.
Madras-Kelly KJ, Ostergaard BE, Baeker Hovde L, Rotschafer JC. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40:627–32.
Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 Suppl A:45–57.
Schentag JJ, Gilliland KK, Paladino JA. Pharmacokinetics and pharmacodynamics of the fluoroquinolones. Clin Infect Dis. 2001; 32 (Suppl l):S39–46.
Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, Schentag JJ. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521–27.
27. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115:19–23S.
Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994; 28:384–89.
Paladino JA, Zimmer GS, Schentag JJ. The economic potential of dual individualization methodologies. PharmacoEconomics 1996; 6:539–45.
Drusano GL, Preston SL, Owens RC, Ambrose PG. Fluoroquinolone pharmacodynamics (correspondence). Clin Infect Dis 2001; 33:2091–2.
Schentag JJ, Gilliland KK, Paladino JA.. Fluoroquinolone pharmacodynamics (reply). Clin Infect Dis 2001; 33:2092–6.
Tarn VH, Louie A, Deziel MR, et al. AUC/MIC ratio and duration of therapy both influence the probability of emergence of resistance to a fluoroquinolone in an in vitro hollow fiber infection model. 39th IDSA meeting, San Francisco, October 25–28, 2001, Clin Infect Dis 2001; 33:1169, Abstract 473.
Orrick J, Ramphal R, Johns T, Russell W. Improving antibiotic susceptibility of Type 1 ß-lactamase producing organisms after formulary replacement of ceftazidime with cefepime. 39th ICAAC meeting, San Francisco, 1999; Abstract #731.
Rifenburg RP, Paladino JA, Bhavnani SM, Den Haese D, Schentag JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health-Syst Pharm 1999; 56: 2217–23.
Bhavnani SM, Forrest A, Collins DA, Paladino JA, Schentag JJ. Association between fluoroquinolone expenditures and ciprofloxacin susceptibility of Pseudomonas aeruginosa among US hospitals. 39th ICAAC meeting, San Francisco, 1999; Abstract #182.
Hill H, Haber M, McGowan J, et al. A link between quinolone use and resistance in P. aeruginosa, Preliminary data from Project ICARE. 39th IDSA meeting, San Francisco, October 25–28, 2001, Clin Infect Dis 2001; 33:1173, Abstract 495.
Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43(7): 1756–8.
Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002; 46: 522–4.
Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 2002; 185: In press.
Hansen G, Blondeau JM, Drlica K, Zhao X. Evaluation of ciprofloxacin and levofloxacin by mutation prevention concentration against 119 isolates of Pseudomonas aeruginosa. 41st ICAAC Meeting, Chicago, 2001; Abstract #E-729.
Blondeau JM, Hansen G, Drlica K, Zhao X. Cmax, MPC, and MIC for the killing of Streptococcus pneumonia by gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. 41st ICAAC Meeting, Chicago, 2001; Abstract #A-2079.
Paladino JA, Sperry H, Backes JM, Gelber J, Jones DA, Cumbo TJ, Schentag JJ. Clinical and economic evaluation of oral ciprofloxacin following an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462–70.
Jensen KM, Paladino JA. Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones. PharmacoEconomics. 1997;11:64–74.
Walters DJ, Solomkin JS, Paladino JA. Cost-effectiveness of ciprofloxacin plus metronidazole vs imipenem/cilastatin in the treatment of intra-abdominal infections. PharmacoEconomics 1999;16 (5 Pt2):551–61.
File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965–72.
Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin versus ceftriaxone/macrolide for the treatment of community-acquired pneumonia. Chest 2001; 119:1439–48.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Paladino, J.A. (2003). Antimicrobial Choices and Dosing Strategies to Maximize Efficacy and Minimize the Development of Bacterial Resistance. In: Doughty, L.A., Linden, P. (eds) Immunology and Infectious Disease. Molecular and Cellular Biology of Critical Care Medicine, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0245-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0245-6_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4984-6
Online ISBN: 978-1-4615-0245-6
eBook Packages: Springer Book Archive